| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-048 |
| filingDate |
1996-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1998-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ece3b671f3aa88d34dbe1e7d5ce3b59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cb99a60c39931855ee885f715734559
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a990da8dab7fa1cd9330a50f451d8774 |
| publicationDate |
1998-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5756480-A |
| titleOfInvention |
Treatment of hyperandrogenic conditions |
| abstract |
The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5α-reductase enzymes from 3-oxo-4-oxa end 4-thiasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5α-reductase enzyme, NADPH. The invention further relates to the isolated inhibitor-cofactor complex. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006003989-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6268377-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0018402-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6187345-B1 |
| priorityDate |
1995-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |